Zimmer Biomet Holdings Inc (ZBH) Shares Bought by Benjamin F. Edwards & Company Inc.

Benjamin F. Edwards & Company Inc. grew its stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 54.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,990 shares of the medical equipment provider’s stock after purchasing an additional 1,058 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Zimmer Biomet were worth $361,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Private Advisor Group LLC boosted its position in shares of Zimmer Biomet by 18.6% during the 3rd quarter. Private Advisor Group LLC now owns 6,733 shares of the medical equipment provider’s stock worth $791,000 after purchasing an additional 1,057 shares in the last quarter. Ingalls & Snyder LLC boosted its position in shares of Zimmer Biomet by 2.6% during the 3rd quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock worth $2,304,000 after purchasing an additional 507 shares in the last quarter. Koch Industries Inc. boosted its position in shares of Zimmer Biomet by 49,697.3% during the 2nd quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock worth $1,033,000 after purchasing an additional 1,038,674 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of Zimmer Biomet by 10.0% during the 3rd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,444 shares of the medical equipment provider’s stock worth $1,925,000 after purchasing an additional 1,494 shares in the last quarter. Finally, Jana Partners LLC boosted its position in shares of Zimmer Biomet by 16.6% during the 3rd quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after purchasing an additional 662,497 shares in the last quarter. Institutional investors own 86.06% of the company’s stock.

Several equities research analysts have commented on ZBH shares. Deutsche Bank upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 target price on the stock in a research report on Tuesday, November 14th. Zacks Investment Research lowered shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday, November 20th. Canaccord Genuity restated a “hold” rating and set a $125.00 target price on shares of Zimmer Biomet in a research report on Tuesday, December 19th. Goldman Sachs Group upgraded shares of Zimmer Biomet from a “sell” rating to a “neutral” rating and set a $125.00 target price on the stock in a research report on Tuesday, December 19th. Finally, Oppenheimer restated a “buy” rating on shares of Zimmer Biomet in a research report on Tuesday, December 19th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $137.42.

Zimmer Biomet Holdings Inc (ZBH) opened at $123.48 on Friday. The stock has a market capitalization of $25,000.00, a price-to-earnings ratio of 38.47, a PEG ratio of 1.90 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47. Zimmer Biomet Holdings Inc has a one year low of $108.03 and a one year high of $133.49.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.02). The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The company’s quarterly revenue was down .8% compared to the same quarter last year. During the same period last year, the firm earned $1.79 EPS. research analysts forecast that Zimmer Biomet Holdings Inc will post 8.03 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, January 29th. Investors of record on Friday, December 29th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.78%. The ex-dividend date is Thursday, December 28th. Zimmer Biomet’s payout ratio is 29.91%.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/01/21/zimmer-biomet-holdings-inc-zbh-shares-bought-by-benjamin-f-edwards-company-inc.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply